{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:33:01Z","timestamp":1784043181113,"version":"3.55.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T00:00:00Z","timestamp":1419206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114519","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T18:54:29Z","timestamp":1419274469000},"page":"e114519","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00327691","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Benoit J.","family":"Arsenault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"DeMicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"LaRosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Greten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette K.","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Treating to New Targets (TNT) Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"P Libby","year":"2002","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1373\/clinchem.2007.097360","article-title":"Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction","volume":"54","author":"RR Packard","year":"2008","journal-title":"Clin Chem"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2005.09.023","article-title":"C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993\u20132003","volume":"187","author":"SM Boekholdt","year":"2005","journal-title":"Atherosclerosis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"PM Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"PM Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","article-title":"C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men","volume":"118","author":"PM Ridker","year":"2008","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C\u2013reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"J Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1093\/eurheartj\/ehm115","article-title":"Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies","volume":"28","author":"N Sarwar","year":"2007","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.7326\/0003-4819-151-7-200910060-00010","article-title":"Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force","volume":"151","author":"M Helfand","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jacc.2010.06.052","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers","volume":"57","author":"BJ Arsenault","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref11","first-page":"1750","article-title":"Retraction notice to "Prediction of cardiovascular events in statin-treated patients by lipid and non-lipid biomarkers"","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"JC LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2008.03.057","article-title":"Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome","volume":"102","author":"U Singh","year":"2008","journal-title":"Am J Cardiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"SE Nissen","year":"2004","journal-title":"Jama"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.clinthera.2008.12.023","article-title":"Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study","volume":"30","author":"J Bonnet","year":"2008","journal-title":"Clin Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial","volume":"114","author":"DA Morrow","year":"2006","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"PM Ridker","year":"2009","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies","volume":"120","author":"E Di Angelantonio","year":"2009","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jacc.2006.08.052","article-title":"N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC\/BHF heart protection study","volume":"49","author":"JR Emberson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/eurheartj\/ehn007","article-title":"The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study","volume":"29","author":"MJ West","year":"2008","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1373\/clinchem.2008.117192","article-title":"Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death","volume":"55","author":"BM Scirica","year":"2009","journal-title":"Clin Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.atherosclerosis.2007.08.011","article-title":"Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia","volume":"197","author":"MC Meuwese","year":"2008","journal-title":"Atherosclerosis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.10.053","article-title":"Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients","volume":"55","author":"KK Koh","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1194\/jlr.P021113","article-title":"Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)","volume":"53","author":"HA Deshmukh","year":"2012","journal-title":"J Lipid Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","article-title":"Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study","volume":"34","author":"JC Hopewell","year":"2013","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"PR Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"R Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1161\/CIRCULATIONAHA.106.666511","article-title":"Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome","volume":"115","author":"KK Ray","year":"2007","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.2337\/db11-0291","article-title":"Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial","volume":"60","author":"HM Colhoun","year":"2011","journal-title":"Diabetes"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:10:52Z","timestamp":1589037052000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114519"}},"subtitle":[],"editor":[{"given":"Jeffrey S.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,22]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114519","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,22]]}}}